Table 1.
Parameter | Non-PVI Group (n = 44) | PVI Group (n = 44) | p-Value |
---|---|---|---|
Age, years [IQR] | 65 [59–72] | 71 [63–74] | 0.05 |
Number of lesions, n [IQR] | 3 [1–6] | 4 [2–9] | 0.59 |
Size of lesions, mm, median [IQR] | 39 [28–56] | 44 [32–68] | 0.62 |
Growth type | |||
nodular, n | 36 | 34 | |
diffuse, n | 8 | 10 | 0.71 |
Non-rim arterial enhancement pattern | |||
hypervascular, n | 23 | 25 | |
hypovascular, n | 4 | 4 | |
mixed, n | 27 | 15 | 0.90 |
Child–Pugh stage | |||
A, n | 22 | 26 | |
B, n | 22 | 17 | |
C, n | 0 | 1 | 0.37 |
AFP levels, ng/mL, mean [IQR] | 11,946 [16–22,316] | 15,193 [38–43,866] | 0.45 |
Etiology | |||
C2, n | 18 | 21 | |
chronic hepatitis B, n | 8 | 6 | |
chronic hepatitis C, n | 12 | 10 | |
NASH, n | 4 | 3 | |
unknown, n | 2 | 4 | 0.83 |
Initial treatment * | |||
curative, n | 10 | 8 | |
intra-arterial, n | 33 | 35 | |
systemic, n | 1 | 1 | 0.87 |
* Curative includes surgery and ablation, intra-arterial includes trans-arterial chemo-embolization and selective internal radiation therapy.